OBJECTIVE: To characterize the pathways induced by transforming growth factor beta1 (TGFbeta1) that lead to the expression of endothelin 1 (ET-1) in human dermal fibroblasts, and to study the effects of TGFbeta1 and ET-1 on the acquisition of a profibrotic phenotype and assess the contribution of the TGFbeta1/ET-1 axis to skin wound healing and fibrosis in vivo. METHODS: The mechanism of induction of ET-1 expression by TGFbeta1 and its effect on the expression of alpha-smooth muscle actin and type I collagen were studied in human dermal fibroblasts, in experiments involving the TGFbeta receptor inhibitor GW788388 and the ET receptor antagonist bosentan, by real-time reverse transcription-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay, immunofluorescence, Western blotting, and promoter/reporter transient transfection analyses. Experiments assessing dermal wound healing in mice were performed with adenovirus-driven overexpression of active TGFbeta1 and ET-1, with or without treatment with bosentan. The contributions of TGFbeta1 and ET-1 to the fibrotic response were also assessed in a mouse model of bleomycin-induced skin fibrosis, by histologic, immunohistochemical, RT-PCR, and protein analyses. RESULTS: TGFbeta1 induced ET-1 expression in human dermal fibroblasts through Smad- and activator protein 1/JNK-dependent signaling. The ability of TGFbeta1 to induce the expression of profibrotic genes was dependent on ET-1. Adenovirus-mediated overexpression of TGFbeta1 and ET-1 in mouse skin was associated with accelerated wound closure, increased fibrogenesis, and excessive scarring. Treatment with bosentan prevented the effects of TGFbeta1. In the bleomycin-induced fibrosis model, treatment with GW788388 and bosentan prevented the fibrotic response. CONCLUSION: Our results strongly support the notion that the TGFbeta1/ET-1 axis has a role in wound repair and skin fibrosis. ET-1 receptor antagonists, such as bosentan, may represent a useful therapeutic tool in the treatment of excessive scarring and fibrosis-related diseases.
OBJECTIVE: To characterize the pathways induced by transforming growth factor beta1 (TGFbeta1) that lead to the expression of endothelin 1 (ET-1) in human dermal fibroblasts, and to study the effects of TGFbeta1 and ET-1 on the acquisition of a profibrotic phenotype and assess the contribution of the TGFbeta1/ET-1 axis to skin wound healing and fibrosis in vivo. METHODS: The mechanism of induction of ET-1 expression by TGFbeta1 and its effect on the expression of alpha-smooth muscle actin and type I collagen were studied in human dermal fibroblasts, in experiments involving the TGFbeta receptor inhibitor GW788388 and the ET receptor antagonist bosentan, by real-time reverse transcription-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay, immunofluorescence, Western blotting, and promoter/reporter transient transfection analyses. Experiments assessing dermal wound healing in mice were performed with adenovirus-driven overexpression of active TGFbeta1 and ET-1, with or without treatment with bosentan. The contributions of TGFbeta1 and ET-1 to the fibrotic response were also assessed in a mouse model of bleomycin-induced skin fibrosis, by histologic, immunohistochemical, RT-PCR, and protein analyses. RESULTS:TGFbeta1 induced ET-1 expression in human dermal fibroblasts through Smad- and activator protein 1/JNK-dependent signaling. The ability of TGFbeta1 to induce the expression of profibrotic genes was dependent on ET-1. Adenovirus-mediated overexpression of TGFbeta1 and ET-1 in mouse skin was associated with accelerated wound closure, increased fibrogenesis, and excessive scarring. Treatment with bosentan prevented the effects of TGFbeta1. In the bleomycin-induced fibrosis model, treatment with GW788388 and bosentan prevented the fibrotic response. CONCLUSION: Our results strongly support the notion that the TGFbeta1/ET-1 axis has a role in wound repair and skin fibrosis. ET-1 receptor antagonists, such as bosentan, may represent a useful therapeutic tool in the treatment of excessive scarring and fibrosis-related diseases.
Authors: David Dolivo; Adrian Rodrigues; Lauren Sun; Yingxing Li; Chun Hou; Robert Galiano; Seok Jong Hong; Thomas Mustoe Journal: Cell Mol Life Sci Date: 2021-06-08 Impact factor: 9.261
Authors: David Alvarez; Paraskevi Briassouli; Robert M Clancy; Jiri Zavadil; Joanne H Reed; Rosanna G Abellar; Marc Halushka; Karen Fox-Talbot; Franck J Barrat; Jill P Buyon Journal: J Biol Chem Date: 2011-07-05 Impact factor: 5.157
Authors: João Abrão; Cleverson R Fernandes; Paul F White; Antonio C Shimano; Rodrigo Okubo; Giovanni Bp Lima; José A Bachur; Sérgio B Garcia Journal: Int Wound J Date: 2012-10-24 Impact factor: 3.315
Authors: Paula B Donate; Thiago M Cunha; Waldiceu A Verri; Cristina M Junta; Flavia O Lima; Silvio M Vieira; Rafael S Peres; Karina F Bombonato-Prado; Paulo Louzada; Sergio H Ferreira; Eduardo A Donadi; Geraldo A S Passos; Fernando Q Cunha Journal: Inflamm Res Date: 2012-01-17 Impact factor: 4.575
Authors: Tetsuo Toyama; Agnieszka P Looney; Brendon M Baker; Lukasz Stawski; Paul Haines; Robert Simms; Aleksander D Szymaniak; Xaralabos Varelas; Maria Trojanowska Journal: J Invest Dermatol Date: 2017-09-01 Impact factor: 8.551
Authors: Melanie R Shakespear; Daniel M Hohenhaus; Greg M Kelly; Nabilah A Kamal; Praveer Gupta; Larisa I Labzin; Kate Schroder; Valerie Garceau; Sheila Barbero; Abishek Iyer; David A Hume; Robert C Reid; Katharine M Irvine; David P Fairlie; Matthew J Sweet Journal: J Biol Chem Date: 2013-07-12 Impact factor: 5.157
Authors: Oscar Busnadiego; Jesús Loureiro-Álvarez; Pilar Sandoval; David Lagares; Javier Dotor; María Luisa Pérez-Lozano; María J López-Armada; Santiago Lamas; Manuel López-Cabrera; Fernando Rodríguez-Pascual Journal: J Am Soc Nephrol Date: 2014-07-10 Impact factor: 10.121